Related Experiment Video
Updated: May 5, 2026
06:33
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
2.0K
Predictors of Early Mortality in Acute Myeloid Leukemia: A Population Based Analysis Using SEER Data
Shahzaib Maqbool1, Mohammad Ebad Ur Rehman2, Ahmad Iftikhar3
1Department of Internal Medicine, HCA Healthcare Kansas City/Centerpoint Medical Center, Independence, MO.
Clinical Lymphoma, Myeloma & Leukemia
|May 3, 2026
Summary
Early mortality in acute myeloid leukemia (AML) remains high, particularly for older adults. Chemotherapy receipt significantly reduces early death risk, and outcomes have improved with newer treatments.
Area of Science:
- Hematology
- Oncology
- Epidemiology
Background:
- Acute myeloid leukemia (AML) presents a significant challenge due to high early mortality rates, disproportionately affecting elderly patients and those with limited healthcare access.
- Understanding predictors of early death is crucial for improving outcomes in AML patients.
Purpose of the Study:
- To identify demographic and disease-related factors associated with early mortality in non-M3 AML.
- To analyze trends in early mortality across different treatment eras.
Main Methods:
- Retrospective cohort analysis of 37,835 non-M3 AML patients from the Surveillance, Epidemiology, and End Results (SEER) 8 database (1975-2022).
- Evaluation of early mortality at 1 month (EM1) and 2 months (EM2) post-diagnosis.
- Binary logistic regression to determine predictors of early mortality, reporting odds ratios (ORs) and 95% confidence intervals (CIs).
Main Results:
- Overall early mortality rates were 33.4% at 1 month and 39.7% at 2 months.
- Mortality significantly increased with age, reaching 52.8% (EM1) and 62.3% (EM2) in patients over 75.
- Chemotherapy receipt substantially reduced early mortality (EM1 OR 0.19, EM2 OR 0.12) and outcomes improved across treatment eras (chemotherapy, HMA, venetoclax).
Conclusions:
- Early mortality in non-M3 AML is significantly influenced by patient age, chemotherapy receipt, and AML subtype.
- Improvements in treatment access and supportive care for high-risk individuals are essential to reduce early deaths.
- Outcomes have progressively improved with advancements in AML treatment strategies.
Related Concept Videos
01:21Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863
01:24Kaplan-Meier Approach
792
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
792
01:20Comparing the Survival Analysis of Two or More Groups
712
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
712